The drug is approved for patients to take a 10 mg dose once daily for 35 days following hip replacement and 12 days following knee replacement surgery. The drug is designed to prevent deep vein thrombosis, which could lead to pulmonary embolism, a major concern for surgeons performing outpatient joint replacement procedures.
Read the release about XARELTO.
Related Articles on Hip and Knee Replacements:
AAOS: 4 New Hip Replacement Studies and Trends
10 Statistics and Facts About Growth in Joint Replacement
Specialized Hospitals Produce Better Hip, Knee Replacement Outcomes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
